Sex: M
Vaccine: ANTH, FLUX, TYP
Symptoms: Eye pain, Fatigue, Headache, Injection site erythema, Injection site pain
Clinical narrative: Case number PHHY2017US011934 is an initial spontaneous report received from Vaccine Adverse Event Reporting System (VAERS reference number: 671683) website on 23 Jan 2017. This report refers to 30 year old male patient. It was reported that patient had a negative health history, and was not taking routing medication at the time of vaccine receipt (treatment noncompliance). Patient had no allergies to medications, foods, latex, and insect stings and denies history of other vaccine adverse events. Concomitant medications were not reported. The patient was vaccinated with seasonal influenza virus vaccine INN (manufacturer unknown, batch number: not reported) intramuscularly on 07 Nov 2015. The patient was vaccinated with first BIOTHRAX (manufacturer unknown, batch number: FAV429A) and typhoid vaccine (manufacturer unknown, batch number: not reported) intramuscularly on 07 Nov 2015. The patient received second BIOTHRAX vaccine on 17 Feb 2016 and reported as the third dose should have been given no earlier than 17 Jul 2016, but patient did not recall receipt of vaccine around this time. On the same day after vaccination, it was reported that within one hour of receiving his first vaccine, patient noted a sharp, pressure-type pain across his forehead, on the top of his head and behind his eyes. Pain intensity was about 5/10 using pain scale of 0 (no pain) to 10 (worst pain ever experienced). It was reported that tho working out, made the pain worse and was associated with increased sensitivity to light. It was reported that the patient had no nausea and vomiting, visual changes, or change in mental status and patient increased his fluid intake and rested and headache resolved after a few hours on an unknown date. It was reported that over the next 2 days, on an unknown date, the patient experienced recurrence of similar headaches and the patient did not self-treat or seek evaluation. It was reported that, after his first anthrax vaccine the affected area was about the diameter of a 12 ounce soda can and symptoms resolved after a few days on an unknown date and after his subsequent anthrax vaccines, the affected area extended from near his shoulder almost to his elbow and resolved after about a week. After second and third anthrax vaccines, on a unspecified dates patient experienced mild body aches and fatigue lasting 2 to 3 days, similar headaches accompanied by photophobia within hours of vaccine receipt and the pain intensity was increased (6 to 8/10) with subsequent vaccine receipt and the patient did not seek evaluation or self-treat headaches, other than increasing fluids and avoiding physical activity. It was reported that the headaches intermittently continued for several weeks following patient second anthrax vaccine, and after his third anthrax vaccine, headaches continued for almost 2 months. Patient has no history of chronic headaches and has not experienced any headaches over the past several months. In addition to experiencing headaches after vaccination, patient also reported experiencing redness, warmth, tenderness, and swelling surrounding his anthrax vaccination sites within 24 hours of vaccine receipt. It was reported that patient did not experience any numbness and tingling or weakness of the affected upper extremity and also denied dyspnea, hives, nasal discharge, facial swelling, dysphagia and lightheadness. It was reported that patient felt well on day of vaccine receipt and was unable to identify any other possible factors contributing to development of symptoms. The final outcome of the vents first occurrence of headache and swelling were reported as complete recovery on an unknown date and for the events eye pain, photophobia, second occurrence of headache and pain were not reported. Seriousness of the events were reported as non serious and causality was not reported.